ES2084338T3 - Anticuerpos recombinantes especificos para el tnf alfa. - Google Patents

Anticuerpos recombinantes especificos para el tnf alfa.

Info

Publication number
ES2084338T3
ES2084338T3 ES92901287T ES92901287T ES2084338T3 ES 2084338 T3 ES2084338 T3 ES 2084338T3 ES 92901287 T ES92901287 T ES 92901287T ES 92901287 T ES92901287 T ES 92901287T ES 2084338 T3 ES2084338 T3 ES 2084338T3
Authority
ES
Spain
Prior art keywords
humanised
antibody molecules
tnf
human
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901287T
Other languages
English (en)
Inventor
John Robert Adair
Diljeet Singh Athwal
John Spencer Emtage
Mark William Bodmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1990/002017 external-priority patent/WO1991009967A1/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of ES2084338T3 publication Critical patent/ES2084338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROVEEN MOLECULAS DE ANTICUERPO RECOMBINANTES, EN PARTICULAR HUMANIZADAS, POR EJEMPLO QUIMERICA HUMANIZADA Y HUMANIZADAS POR CDR-INJERTO, QUE TIENEN ESPECIFICIDAD PARA EL TNFALFA HUMANO PARA USO EN DIAGNOSIS Y TERAPIA. EN PARTICULAR LAS MOLECULAS DE ANTICUERPO TIENEN LUGARES DE ENLACE ANTIGENO DERIVADOS DE ANTICUERPOS MONOCLONALES DE MURINA CB0006, CB0010, HTNF3 O 101,4. LOS ANTICUERPOS ANTI HTNFALFA IDONEOS HUMANIZADOS POR CDR-INJERTO COMPRENDEN DOMINIOS VARIABLES QUE COMPRENDEN UN CUADRO ACEPTEDOR HUMANO Y REGIONES DE ENLACE ANTIGENO DE DONANTE Y DONDE LOS CUADROS COMPRENDEN RESIDUOS DEL DONANTE EN POSICIONES ESPECIFICAS. LAS MOLECULAS DE ANTICUERPO SE PUEDEN UTILIZAR EN EL TRATAMIENTO TERAPEUTICO DE PACIENTE HUMANOS QUE SUFRAN O ESTEN EN RIESGO DE ENFERMEDADES ASOCIADAS CON NIVELES ELEVADOS INDESEABLES DE TNF, EN PARTICULAR PARA EL TRATAMIENTO DE ENFERMEDADES INMUNOREGULATORIAS E INFLAMATORIAS O DE CHOQUE SEPTICO, ENDOTOXICO O CARDIOVASCULAR.
ES92901287T 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para el tnf alfa. Expired - Lifetime ES2084338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies
GB919109645A GB9109645D0 (en) 1991-05-03 1991-05-03 Recombinant antibodies

Publications (1)

Publication Number Publication Date
ES2084338T3 true ES2084338T3 (es) 1996-05-01

Family

ID=10694434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92901287T Expired - Lifetime ES2084338T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para el tnf alfa.
ES94201456T Expired - Lifetime ES2190434T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para tnf-alfa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94201456T Expired - Lifetime ES2190434T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para tnf-alfa.

Country Status (21)

Country Link
US (1) US20030199679A1 (es)
EP (3) EP0927758A3 (es)
JP (3) JP3145401B2 (es)
KR (1) KR100253426B1 (es)
AT (2) ATE134387T1 (es)
AU (2) AU657937B2 (es)
BR (1) BR9106232A (es)
CA (3) CA2329482C (es)
DE (4) DE69117284T2 (es)
DK (2) DK0626389T3 (es)
ES (2) ES2084338T3 (es)
FI (1) FI109800B (es)
GB (2) GB9109645D0 (es)
GR (1) GR3019066T3 (es)
HU (2) HUT62661A (es)
NL (1) NL9120013A (es)
NO (2) NO923231L (es)
NZ (2) NZ241147A (es)
OA (1) OA09666A (es)
PT (1) PT99934B (es)
WO (1) WO1992011383A1 (es)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
EP0614984B2 (en) † 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
EP0753065B1 (en) 1994-03-29 2003-05-14 Celltech Therapeutics Limited Antibodies against e-selectin
DK0813423T3 (da) * 1995-01-23 2002-07-22 Xenotech Inc Præparat til forebyggelse af osteolysis og metastase
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20140212413A1 (en) * 1995-12-11 2014-07-31 New York University Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
EP0791360A3 (en) * 1996-02-29 1997-09-24 Bayer Corporation Treatment of septic shock with anti-TNF antibodies
EP0925294B3 (en) 1996-07-24 2018-07-04 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
EP2177517B1 (en) 1996-07-24 2011-10-26 Celgene Corporation Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
ES2332435T3 (es) * 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited Vector dirigido a tumores.
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
EP1032420A4 (en) * 1997-11-14 2004-09-15 Euro Celtique Sa IMMUNOGLOBULIN MOLECULES WITH SYNTHETIC VARIABLE REGION AND MODIFIED SPECIFICITY
RU2001121987A (ru) * 1999-03-18 2004-02-27 Селджин Корпорейшн (Us) Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7026491B2 (en) 2000-07-21 2006-04-11 Chugai Seiyaku Kabushiki Kaisha Coumarin derivatives useful as TNFα inhibitors
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
WO2003083071A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
ES2370710T3 (es) 2002-05-28 2011-12-22 Ucb Pharma, S.A. ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
JP2007525409A (ja) * 2003-01-08 2007-09-06 アプライド モレキュラー エボリューション，インコーポレイテッド ＴＮＦ−α結合分子
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
BRPI0611765B1 (pt) * 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
CA2623648C (en) * 2005-09-21 2018-05-22 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
JP5259423B2 (ja) * 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
BRPI0711908B8 (pt) * 2006-05-25 2021-05-25 Glaxo Group Ltd anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
US8680252B2 (en) 2006-12-10 2014-03-25 Dyadic International (Usa), Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CA2703621C (en) 2007-11-09 2022-03-22 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
CN101969929B (zh) 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
JPWO2009142186A1 (ja) * 2008-05-20 2011-09-29 株式会社カネカ 細胞障害性組成物
PL2307457T5 (pl) * 2008-06-25 2022-12-27 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące tnf
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
AU2011237679B2 (en) * 2010-04-07 2014-11-06 Abbvie Inc. TNF-alpha binding proteins
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
CN105793439B (zh) * 2013-11-06 2020-09-04 阿斯图特医药公司 以生物样品进行的针对igfbp7的具有改进的性能的测定
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017158079A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
ES2843974T3 (es) 2016-03-17 2021-07-21 Tillotts Pharma Ag Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos
EP3430042B1 (en) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
SI3219726T1 (sl) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
WO2019106609A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20210070854A1 (en) * 2017-12-29 2021-03-11 Board Of Regents, The University Of Texas System Antimicrobial nanobodies
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
CN113631574A (zh) 2019-01-31 2021-11-09 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4261222A1 (en) 2020-12-09 2023-10-18 HK inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
EP0355067A1 (en) * 1988-08-19 1990-02-21 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
ES2156859T5 (es) * 1991-03-18 2008-03-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
EP0614984B2 (en) * 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies

Also Published As

Publication number Publication date
FI923737A0 (fi) 1992-08-20
GR3019066T3 (en) 1996-05-31
EP0626389B1 (en) 2002-12-04
DK0626389T3 (da) 2003-03-31
PT99934A (pt) 1993-01-29
NO923231L (no) 1992-10-20
CA2076540A1 (en) 1992-06-22
ATE228853T1 (de) 2002-12-15
HUT62661A (en) 1993-05-28
GB9217880D0 (en) 1992-10-28
WO1992011383A1 (en) 1992-07-09
NO923231D0 (no) 1992-08-18
DE4193302T1 (de) 1993-02-18
NL9120013A (nl) 1992-11-02
EP0927758A3 (en) 2001-02-21
GB2257145B (en) 1995-06-14
FI923737A (fi) 1992-08-20
DK0516785T3 (da) 1996-03-18
CA2329482C (en) 2001-12-11
US20030199679A1 (en) 2003-10-23
HU9202605D0 (en) 1992-10-28
EP0626389A1 (en) 1994-11-30
CA2129554C (en) 1998-12-29
PT99934B (pt) 1998-08-31
JPH10136986A (ja) 1998-05-26
NZ241147A (en) 1995-04-27
FI109800B (fi) 2002-10-15
CA2076540C (en) 2001-03-27
JPH05507418A (ja) 1993-10-28
KR100253426B1 (ko) 2000-04-15
EP0927758A2 (en) 1999-07-07
ES2190434T3 (es) 2003-08-01
DE69133167D1 (de) 2003-01-16
CA2129554A1 (en) 1992-06-22
GB2257145A (en) 1993-01-06
DE69133167T2 (de) 2003-07-24
EP0516785A1 (en) 1992-12-09
BR9106232A (pt) 1993-03-30
AU669083B2 (en) 1996-05-23
JP3383795B2 (ja) 2003-03-04
ATE134387T1 (de) 1996-03-15
JP2001114697A (ja) 2001-04-24
DE4193302C2 (de) 2000-08-24
GB9109645D0 (en) 1991-06-26
AU7772394A (en) 1995-03-09
EP0516785B1 (en) 1996-02-21
AU657937B2 (en) 1995-03-30
NZ260226A (en) 1995-04-27
HU211626A9 (en) 1995-12-28
OA09666A (en) 1993-05-15
CA2329482A1 (en) 1992-06-22
JP3145401B2 (ja) 2001-03-12
NO20012882L (no) 1992-10-20
NO20012882D0 (no) 2001-06-11
DE69117284T2 (de) 1996-09-05
DE69117284D1 (de) 1996-03-28
AU9108491A (en) 1992-07-22

Similar Documents

Publication Publication Date Title
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
FI973120A (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
DK0945464T3 (da) Specifikke bindingselementer for human TGF-beta; materialer og metoder
ATE240395T1 (de) Antikörper gegen e-selektin
FI901344A0 (fi) Monoklonala antikroppar reaktiva med tnf.
DE10199067I2 (de) Fuer Menschlichen Tumornekrose-Faktor spezifische Monoklonale und Chimaere Antikoerper
MY145703A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
ATE179210T1 (de) Gentechnologisch hergestellte antikörper
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 516785

Country of ref document: ES